3 mg QD to 15 mg QD PF-06649751 for parkinson disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trials ended early. Its trials were stopped early. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 14 Jun 2017: Trial registered, NCT03185481
  2. 6 Jul 2017: Trial started, NCT03185481
  3. 25 Oct 2017: Trial terminated, NCT03185481
  4. 12 Apr 2019: Trial results posted, NCT03185481

The trials

NCT03185481: Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

State
Stopped early
Phase
Phase 2
People
5 taking part
Started
6 Jul 2017
Primary completion
24 Oct 2017
Arms
3 mg QD to 15 mg QD PF-06649751
Results
Posted on the registry
  1. 14 Jun 2017: Trial registered
  2. 6 Jul 2017: Trial started
  3. 25 Oct 2017: Trial terminated
  4. 12 Apr 2019: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Trials ended early

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.